Afamelanotide in the Treatment of Dermatologic Disease

Authors

Morgan M. McNeil
Amanda F. Nahhas, Henry Ford HealthFollow
Taylor L. Braunberger, Henry Ford HealthFollow
Iltefat H. Hamzavi, Henry Ford HealthFollow

Recommended Citation

McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH. Afamelanotide in the Treatment of Dermatologic Disease. Skin therapy letter 2018; 23(6):6-10.

Document Type

Article

Publication Date

11-1-2018

Publication Title

Skin therapy letter

Abstract

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE), vitiligo, acne, and Hailey-Hailey disease. Its relatively low risk side effect profile makes it an attractive treatment option and also paves the way for innovative use in other disorders.

PubMed ID

30517779

Volume

23

Issue

6

First Page

6

Last Page

10